Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Studying Health Outcomes after Treatment in Patients with Retinoblastoma, RIVERBOAT Study

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma.
Pediatrics, Retinoblastoma (Pediatrics)
N/A
Children
Not Available
Not Available
Friedman, Debra
Local
Children's Hospital of Philadelphia, Cincinnati Children's Hospital, M.D. Anderson Cancer Center, Houston, Medical College of Wisconsin, Northwestern University, Texas Children's Hospital, The Hospital for Sick Children - Toronto, University of Illinois-Chicago, University of Minnesota, Vanderbilt University, Washington University
01-24-2019
Health Services Research
VICCPED1878
NCT03932786

Eligibility

0 Years
BOTH
YES
Inclusion Criteria:

Unilateral or bilateral intraocular retinoblastoma.

Diagnosis between the ages of 0 - 17.99 years.

Diagnosis on or after January 1, 2008.

No exclusions based on primary or secondary treatment modalities.

Retrospective group patients must be >= 6 months post end of treatment at study entry * For those already at this timepoint, they are now eligible * For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are >= 6 months post end of treatment * Prospective group patients must not have begun treatment

Patients with diminished capacity will not be enrolled.

Patients must be able to communicate in English, French, or Spanish.

Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient.

All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: